MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD DisclosureITEM 7.01
REGULATION FD DISCLOSURE.
MABVAX THERAPEUTICS HOLDINGS, INC. (NASDAQ:MBVX) Files An 8-K Regulation FD Disclosure
On February 12, 2018, MabVax Therapeutics Holdings, Inc. (the “Company”) issued a press release announcing positive interim data from expanded cohort in a Phase 1 trial evaluating MVT-5873 in combination with first-line chemotherapy in pancreatic cancer. The press release is attached hereto as Exhibit 99.1.
The information disclosed under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, except as expressly set forth in such filing.
|
ITEM 9.01 |
FINANCIAL STATEMENTS AND EXHIBITS |
(d)Exhibits.
The exhibit listed in the following Exhibit Index is furnished with this Current Report on Form 8-K.
|
Exhibit No. |
Description |
|
Press Release dated February 12, 2018 |
MABVAX THERAPEUTICS HOLDINGS, INC. ExhibitEX-99.1 2 ex99-1.htm PRESS RELEASE Blueprint Exhibit 99.1 MabVax Therapeutics Announces Positive Interim Data from Expanded Cohort in Phase 1 Trial Evaluating MVT-5873 in Combination with First-Line Chemotherapy in Pancreatic Cancer ● All treated patients had measurable tumor reductions ● Promising early results merit additional enrollment ● Company aiming to establish the potential of combination of MVT-5873 with first line therapy in pancreatic cancer SAN DIEGO,…To view the full exhibit click here
